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Abstract
Background: The nature and magnitude of adverse drug events (ADEs) among hospitalized children in low-income
countries is not well described. The aim of this study was thus, to assess the incidence and nature of ADEs in hospitalized
children at a teaching hospital in Ethiopia.
Methods: We used prospective observational method to study children that were hospitalized to Jimma University
Specialized Hospital between 1 February and 1 May 2011. ADEs were identified using review of treatment charts,
interview of patient and care-giver, attendance at ward rounds and/or meetings and voluntary staff reports. Two senior
pediatric residents evaluated the severity and preventability of ADEs using preset criteria. Logistic regression analysis was
employed to determine predictors of ADEs.
Results: There were 634 admissions with 6182 patient-days of hospital stay. There were 2072 written medication orders
accounting for 35,117 medication doses. Fifty eight ADEs were identified with an incidence of 9.2 per 100 admissions, 1.7
per 1000 medication doses and 9.4 per 1000 patient-days. One-third of ADEs were preventable; 47 % of these were due
to errors in the administration stage of medication use process. Regarding the severity of ADEs, 91 % caused temporary
harms and 9 % resulted in permanent harm/death. Anti-infective drugs were the most common medications associated
with ADEs. The occurrence of ADEs increased with age, length of hospital stay, and use of CNS, endocrine
and antihistamine medicines.
Conclusion: ADEs are common in hospitalized children in low-income settings; however, one-third deemed preventable.
A strategy to prevent the occurrence and consequences of ADEs including education of nurses/physicians is of paramount
importance.
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Background
Adverse events, injuries that occur during medical man-
agement, have received attention after the Harvard Medical
Practice Study [1, 2]. Brennan et al. [1] estimated that 3.7 %
of all hospitalized patients experienced an adverse event. In
1999, the Institute of Medicine of USA [3] reported that
preventable medication related events alone could result in
7000 deaths annually.
Despite the extensive literature on adverse events due
to medications (also known as adverse drug events) in
adult populations, there is scarcity of published study on
pediatric-specific adverse drug events (ADEs) [4, 5]. But,
there are suggestions that harm to medication use might
be higher in children than in adults [6]. The rate of
pediatric ADEs rates can range from 6.6 to 15.7 events
per 1000 patient-days [4, 7] and 1.2 per 1000 medication
doses [7], with a potential ADE rate of 10 per 100 admis-
sions [8]. However, studies that utilized adverse drug reac-
tion (ADR) as an outcome reported a higher incidence of
ADRs in pediatric inpatients, 10 to 17 % [9–14]. More-
over, in another meta-analysis of prospective studies the
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overall incidence of ADRs was found to be 9.5 %; severe
reactions accounted for 12.3 % of the total [15].
The incidences of adverse drug events may vary depend
on study definitions and detection methods. The available
methods of detection include voluntary reporting [16–18],
patient interviews and chart reviews [16], trigger tools [19]
and computerized monitoring systems [20–23]. While
spontaneous reporting underestimates the real incidence
of ADEs [24], the use of computerized monitoring system
generates the best results [22, 23]. Since there is no single
best method [20], the use of multiple strategies maximizes
the incidence of ADE quantification [23].
ADEs are a major burden on healthcare; the conse-
quences can vary from temporary/permanent harms [25] to
costs associated with ADE management [3, 9, 26–28] and
prolonged hospital stay [29, 30]. Studies have shown that
2 % of hospital admissions are due to ADEs in the
pediatrics [12, 31], but a higher admission is reported
in patients with off-label use of medications, 11 %
[32]. A Canadian study in the pediatric patients de-
scribed that 8 % of emergency department visits were
attributed to medication-related events, of which two-
third were deemed preventable [33]. However, there is
paucity of information with regard to the magnitude
of ADEs in hospitalized children in developing countries
including Africa. Thus, the aim of this study was to assess
the incidence and nature of ADEs in hospitalized children
in the pediatric ward of a teaching hospital in Ethiopia.
Methods
Study setting and design
This prospective observational study was conducted in the
pediatric ward of Jimma University Specialized Hospital
(JUSH), Ethiopia, which had a bed capacity of 503. The
hospital was providing both outpatient and inpatient
pediatric services for children less than 14 years. During
the study period, the inpatient department had four units
i.e., critical care, neonatal (for neonates ≤ 14 days of age),
nutritional rehabilitation and general. There were 4 pedia-
tricians, 5 senior residents, 12 junior residents and 20
nurses during the study period.
All pediatric inpatients that were hospitalized between
1 February and 1 May 2011 were included. Patients were
excluded if the hospital admission was for less than
24 h, and/or if the admission was the result of an
intentional (self-administered) overdose. All admitted
pediatric patients were followed for the main outcome
measure (occurrence of actual ADEs) from admission to
discharge/transfer/death. In addition, the preventability
and severity of each ADE episode was evaluated.
Data collection and ADE case evaluation
ADE was defined as any incident resulting in injury from
any stage of the medication use process (ordering,
transcribing, dispensing, administrating and monitoring)
[34]. A preventable ADE was an injury due to an error
at any stage in the medication use - for instance,
hypoglycemia due to insulin overdose. Non-preventable
ADE was an injury not related to error in the medication
process. An allergic reaction in a patient not previously
known to be allergic to the medication is an example of
non-preventable ADE.
A combination of methods was employed to identify
ADEs. From the patient medical record, one nurse &
two pharmacists collected the following demographic
and clinical data from medical records of participants
using a structured format: age, gender, history of previous
medication and drug allergy, admission diagnoses, current
drug dosage and regimen and length of hospital stay.
Charts were reviewed daily until discharge/transfer/death
of the child. Moreover, changes in medication regimens
including discontinuation or initiation of new medications
and abnormal laboratory values were recorded. A list of
pediatric trigger tools, these are drugs or clues that have
links to potential ADEs because either they are antidotes
or given to reverse the action of a drug responsible for
ADE, was adapted from US organizations [35, 36] and
modified based on availability of medicines in Ethiopia
[37] (Additional file 1).
In case of medication management changes, the re-
sponsible physician was contacted for clarification.
Evaluation was made whether the change was due to
ADE. Besides, we asked the pediatric ward staff to report
any actual events or potentially unsafe medication sys-
tems that was noticed. A clinical pharmacist was attend-
ing clinical rounds/meetings and visited the ward daily
to solicit any alerts for ADE. The clinical pharmacist for-
warded any suspected ADE cases for further evaluation
to a multidisciplinary team comprised of senior attend-
ing physician, pediatric resident, nurses and pharmacists.
Once decided by the multidisciplinary, the suspected
ADE was assessed for temporal relationship between the
drug and the event as per WHO-UMC criteria [38].
The response to withdrawal plausibility, if possible was
also evaluated. Those in the category of possible, prob-
able/likely and certain were considered. We searched
biomedical literatures to establish the strength of published
data, if any, on the relationship between the ADEs and the
medication. During this evaluation, the expertise of the
pediatrics team was used when required for further work-
up especially on the exclusion of possible disease condition.
Since ADEs were actual patient harms, a specific medical
care was given when applicable to prevent further damage.
For categorizing severity of ADEs, the National Coord-
inating Council for Medication Error Reporting and Pre-
vention (NCC MERP) scale was employed [39]. Each
event was assigned a harm level of E - I. Severity cat-
egory E, F, G, H and I referred to temporary harm to the
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patient requiring intervention, temporary harm to the
patient requiring initial or prolonged hospitalization,
permanent harm to the patient, intervention required to
sustain life, e.g. cardiovascular/respiratory support and
death of the patient respectively.
Preventability was determined using the explicit cri-
teria developed by Schmumock and Thornton [40].
Categorization of events (severity and preventability)
was evaluated by a panel of two senior pediatric resi-
dents, who independently classified the events using pre-
set criteria. The reviewers reached consensus through
discussion for discordant classification.
Data analysis
Data were analyzed using Statistical Package for the
Social Sciences (SPSS Inc., Chicago, IL, USA) version
16. Qualitative variables were described as frequencies
(percentages) and quantitative variables as mean ± standard
deviation (SD). Each ADE was treated in the analysis as a
separate independent ADE. ADE incidence was calculated
per 100 admissions, per 1000 patient-days, per 1000 medi-
cation doses and per 100 medication orders. Kappa statis-
tics were used to determine inter-rater reliabilities.
Covariates for occurrence of ADEs were evaluated
using logistic regression analysis. The covariates were
number of medications ordered, length of hospital
stay, age, medication class and presence of infectious dis-
ease. Odds ratio (crude and adjusted) with its p-value and
95 % confidence interval was reported. A p-value <0.05
was considered statistically significant.
Ethical consideration
Ethical approval was obtained from Ethical Review
Board of Jimma University. Patient/caregiver/family
member gave verbal consent for the information re-
quired. Appropriate interventions were recommended to




A total of 699 admitted patients were followed. Among
these, 65 admissions were excluded (length of stay less than
24 h and/or insufficient data). We included 634 admissions
representing 600 patients for analysis.
Pediatrics of various ages were included (minimum
7 days, maximum 14 years). The mean age of the patients
was 2.9 years, 371 (61.8 %) were males and 215 (33.9 %)
infants (Fig. 1). The length of hospital stay was 6182
patient-days. A total of 2072 medication orders were writ-
ten accounting for 35,117 medication doses and 55.4
medication doses per admission. Of those included in the
analysis, 15 (2.5 %) admissions didn’t receive any medica-
tion during their hospital stay. The mean ± SD length of
hospital stay and medications ordered were 9.8 ± 8.8 days
and 3.3 ± 1.9 respectively.
The top 10 admitting diagnosis were severe pneumonia
173 (27.3 %), severe acute malnutrition 120 (18.9 %),
early/late onset neonatal sepsis 108 (17.0 %), meningitis
59 (9.3 %), acute gastroenteritis 46 (7.3 %), malaria 39
(6.2 %), anemia’s of different causes 43 (6.8 %), first epi-
sode of wheeze 32 (5.1 %), congestive heart failure 27
(4.3 %) and soft tissues abscess 26 (4.1 %). Anti-infective
drugs, 1330 (64.2 %) were the leading class of medications
prescribed followed by drugs acting on the central ner-
vous system (CNS), 206 (9.9 %) (Table 1).
Incidence, preventability and severity of ADEs
A total of 58 ADEs were identified in 46 patients. The
incidences of ADEs were found to be 9.2 per 100 admis-
sions (crude rate), 1.7 per 1000 medication doses, 9.4
per 1000 patient days and 2.8 per 100 medication orders.
The majority of ADEs occurred in the general pediatric
ward, 33 (56.9 %) followed by the critical unit, 21
(36.2 %). Twelve patients had more than 1 ADEs during
hospitalization. 4 of the 58 (6.9 %) ADEs were the pri-
mary reasons for hospitalization i.e. these ADEs were a
cause of hospital admissions. For example, a child with
Fig. 1 The age category of hospitalized children in Jimma University Specialized Hospital
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known type I diabetes was admitted as result of severe
hypoglycemia following insulin injection.
Thirteen (22.4 %) of the ADEs were injection site
phlebitis (pain, swelling and redness) and 12 (20.7 %)
were maculopapular skin rash with or without urticaria
(Table 2). Of the 58 ADEs, the reviewers classified 39
(67.2 %) as non-preventable and 19 (32.8 %) as
preventable. Among the preventable ADEs, 9 (47 %)
were following errors in the administration stage of
medication use process, 8 (42 %) due to improper dos-
age and 2 (11 %) were attributed to monitoring errors.
Examples of preventable ADEs are listed in Table 3.
Majority of the ADEs were of temporary harms i.e. 39
(67 %) category E, and 14 (24 %) category F. Only 5
(9 %) of the ADEs resulted in permanent harm/death.
Three out of four permanent harms were due to wrong
administration of drugs. There was one death associated
with monitoring error; it was most likely due to a
failure to use appropriate clinical or laboratory data
to monitor response to crystalline penicillin prescri-
bed for severe pneumonia. The level of agreement be-
tween reviewers for severity rating of ADE was “good”
(Kappa = 0.65) whereas it was “moderate” (Kappa = 0.46)
for preventability.
Anti-infective was the most common medication class
responsible for the ADEs (Table 4). Injection site phlebitis,
skin rash with/without urticaria and antibiotic associated
colitis were the common ADEs associated with anti-
infectives. Of 58 ADEs, 21 (36.2 %) were detected in in-
fants and 14 (24.1 %) in school-age children. Thirty nine
(67.2 %) of all the ADEs occurred with IV route of admin-
istration and 16 (27.6 %) followed oral route. Drugs were
used to manage 30 (51.7 %) ADEs while the offending
drugs were discontinued in 16 (27.6 %) cases. Fifteen
(25.8 %) ADEs required increased monitoring of vital signs
and/or laboratory values (e.g. serial of random blood glu-
cose level determinations) and 4 (6.9 %) ADEs required
dose reduction. Other interventions included change of
the IV injection site, saline flushing of the IV line, daily
wound care and abscess drainage.
In the multivariable analysis, length of stay greater than
23 days (AOR 8, 95 % CI: 2.93, 22.04), presence of in-
fectious disease (AOR 3.43, 95 % CI: 1.19, 9.91), use
of anti-histamines and anti-allergic (AOR 32.5, 95 % CI:
6.0, 176.45), CNS (AOR 2.09, 95 % CI: 1.01, 4.32) and
endocrine (AOR 3.38, 95 % CI: 1.40, 8.15) medicines were
associated with occurrence of ADEs (Table 5).
Discussion
In countries with better resources, medication safety
programs are well integrated with the health care system
[7, 9, 10]. In low income countries like Ethiopia, how-
ever, healthcare coverage is prioritized to medication
safety. Moreover, the medication use system is not evi-
dence based. To our knowledge, this is the first study
from Ethiopia assessing the extent of ADEs in children
and hence, this study will provide baseline data for patient
safety advocates.
Estimation of the incidence of ADEs significantly de-
pends on the trigger to which the event was searched,
the methodology and definition used. The incidence
Table 1 Frequency of medication classes prescribed for
hospitalized children in Jimma University Specialized Hospital
Codeb Medication class Frequency of
prescription (N = 2072),
%
AI.000 Anti-infective medicines 1330 (64.2)
NS.000 Central nervous system
medicines
206 (9.9)
VT.000 Vitamins 158 (7.6)
CV.000 Cardiovascular medicines 103 (5.0)
RE.000 Respiratory medicines 66 (3.3)
ED.000 Medicines used in endocrine
disorders
66 (3.3)
OP.000 Ophthalmic agents 30 (1.5)
BL.000 Blood products and medicines
affecting the blood
28 (1.4)
DE.000 Dermatological agents 25 (1.2)
GI.000 Gastrointestinal medicines 20 (1.0)
AL.000 Antihistamines and anti-
allergic medicines
10 (0.5)




—————— Othersa 25 (1.2)
aOther includes calcium gluconate, calvitalis® (consisted of calcium and other
9 vitamins), magnesium sulfate, etc
bCode given is based on Pharmacologic – Therapeutic classification scheme
used in the list of medicines in Ethiopia, 2010 [37]; this schematic classification
is analogous to ATC codes employed elsewhere
Table 2 Types of ADEs identified clinically among children
admitted in Jimma University Specialized Hospital
Adverse drug event n (%)
Injection site phlebitis 13 (22.4)
Skin rash with/without urticaria 12 (20.7)
N/V, dyspepsia (+/− loss of appetite)a 7 (12)
Antibiotic associated diarrhea 6 (10.3)
Infiltration, subcutaneous 3 (5.2)
Oral candidiasis 2 (3.4)
Extravasation induced tissue necrosis 2 (3.4)
Othersb 16 (27.6)
aN/V (nausea or vomiting), +/− (with or without)
bIncludes hypotension, tachycardia, pain/burning sensation at injection site,
hypoglycemia, congestive heart failure (aggravated), acute dystonic reaction,
rectal irritation (proctitis), gangrene, gingival hypertrophy/facial coarsening,
DKA/hyperglycemia, over sedation, irritability, exoflative dermatitis, seizure,
headache/abdominal pain and death
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rates of ADEs in our study were higher when compared
with two studies in the USA; 6 per 100 admissions and 7.5
per 1000 patient-days [41] and 2.3 per 100 admissions and
6.6 per 1000 patient-days [4]. But the rates were lower
than a finding from New Zealand study (12.9 per 100
admissions and 22.1 per 1000 patient-days) [9]. Another
study from USA [7], conducted through a retrospective
focused chart review and pediatric trigger tools, reported
an ADEs incidence of 11.1 per 100 admissions, 15.7 per
1000 patient-days and 1.23 per 1000 medication doses. A
similar study definition was employed in Takata et al.
study [7], but a little bit higher ADE incidence was re-
ported. It shouldn’t be mistakenly noticed that our finding
is lower than that of the USA because of the methodology
used is different (retrospective, focused chart review). But,
when we compared with Kaushal et al. [4] and Holdsworth
et al. [41] studies that used similar methods, we found a
higher rate of ADEs.
Comparing the preventability of ADEs in our study
with previous studies, different authors reported differ-
ent figures: Holdsworth et al. [41] 61 %, Kaushal et al.
[4] 19.2 %, Kunnac et al. [9] 57 % and Takata et al. [7]
29 %. In this study, the most common medication errors
responsible for preventable ADEs were errors occurred
during administration and improper dose (dose too
low/high). According to Takata et al. [7], most of prevent-
able ADEs occurred during monitoring stage; defined as a
failure to use appropriate clinical or laboratory data for
adequate assessment of patient response to prescribed
therapy.
In this study, the severity rating for observed ADEs
showed that around 91 % resulted in temporary harm
(either category E or G). Takata et al. [7], reported
that all of the ADEs they detected caused temporary
harm. Other than the NCC MERP scale, other previous
studies also reported serious to life-threatening events in
24–34 % of ADEs [4, 41], and permanent harms in 5 % of
ADEs [41]. Thus, comparatively the severity of ADEs in
our study (9 % resulted in permanent harm/death) was
very high. In this study, 3 of the 4 events that resulted in
permanent harm were due to inadvertent route of admin-
istration of medication, and were classified as preventable.
The incidence of ADEs was comparable with most previ-
ous reports, but we can still appreciate that hospitalized
children in our setting were facing a considerable amount
of preventable medication-related permanent harm.
In our study, injection site phlebitis was the commonest
ADEs detected. Kaushal et al. [4] reported, two third of
non-preventable ADEs were related to antibiotic associated
Clostriduim difficile infections, rashes, allergic reactions
and yeast infection. Again similar findings were reported by
Takata et al. [7] where pruritus was the most common
ADE.
In our study, the most common medication class re-
sponsible for the ADEs was anti-infectives. This medica-
tion class was also the most commonly used medication
classes among all study participants. In other studies, the
most commonly cited medication classes associated with
ADEs were analgesics/opioids followed by antibiotics
[7, 41]. Opioids are mentioned frequently as a cause
Table 3 Examples of preventable ADEs that occurred at different stages of the medication use process in children admitted in
Jimma University Specialized Hospital
Stage of error Description of case
Administration A child admitted with newly diagnosed type I DM without DKA developed moderate DKA while in the hospital due to omissions of
insulin dose
For a newborn, a nurse secured IV line and inadvertent intra-arterial administration of Ampicillin and Gentamicin lead to extravasation
induced necrosis
A child with pharyngitis who was taking IV cloxacillin developed infiltration at the injection site
Prescribing An 8 year old severely malnourished child with the diagnosis of CHF secondary to chronic valvular heart disease was receiving Lasix
20 mg PO BID, and digoxin 0.125 mg P.O per day, who latter developed irritability
Over sedation due to an overdose of tramadol in a child with moderate pain
A child developed maculopapular rash with urticaria to cloxacillin with previous history of penicillin allergy
Monitoring A 6 month infant with severe pneumonia was put on crystalline penicillin but failure to use appropriate clinical or laboratory data for
adequate assessment of patient response to prescribed therapy cause the death of a patient
BID (bis in die) twice daily, CHF congestive heart failure, DM diabetes mellitus, DKA diabetic ketoacidosis, PO per oral
Table 4 The classes of medications responsible for adverse
drug events among children hospitalized in Jimma University
Specialized Hospital
Medication classa n (%)
Anti-infective medicinesb 42 (72)
Cardiovascular medicines 4 (7)
Central nervous system medicines 4 (7)
Respiratory medicines 3 (5)
Medicines used in endocrine disorders 3 (5)
Gastrointestinal medicines 1 (2)
Medicines affecting the blood 1 (2)
aClassification is based on Pharmacologic – Therapeutic classification scheme
used in the list of medicines in Ethiopia, Sept 2010 [37]
bFor one ADE, the maintenance fluid (isotonic normal saline) also contributed
for infiltration in additions to anti-infectives being used
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of ADEs in the literature but they were not available
in JUSH during the study period.
Additional interventions were required to manage
ADEs. ADE management was mostly done through pre-
scriptions of additional medications followed by discon-
tinuation of the offending agent. These additional
interventions can predict the impact of ADE on this
hospital as well as to the patient. In developing countries
like Ethiopia, these interventions are associated with
immense cost imposition to the health system.
Presence of infectious disease, use of antihistamines
and anti-allergic, CNS and endocrine medicines was
associated with occurrence of ADEs. The use of anti-
histamine and anti-allergic medications were strongly
associated with ADEs. This interpretation should be in
caution, however. None of the antihistamine and anti-
allergic drugs were implicated in causing ADEs, but 6 of
the 10 prescriptions were written for reversing the causality.
This correlates well to the notion that during monitoring
for occurrence of ADEs, the use of anti-histamines and
Table 5 Odds ratio for factors associated with ADEs among children hospitalized in Jimma University Specialized Hospital
Characteristics ADEs occurred Crude OR
(95 % CI)
Adjusted ORb
(95 % CI)Yes (n = 46) No (n = 588)
Number of medications ordereda
1–5 34 512 1.0 1.0
6–10 11 58 2.86 (1.37–5.94) ** 0.76 (0.26–2.18)
≥11 1 3 5.02 (0.51–49.55) 0.17 (0.00–11.22)
Length of hospital stay
1–8 12 352 1.0 1.0
9–15 11 132 2.56 (1.10–5.95) ** 2.47 (1.00–6.14)
16–22 11 62 5.20 (2.20–12.32)* 5.06 (1.98–12.94) **
≥23 12 42 8.38 (3.54–19.84) * 8.04 (2.93–22.04) *
Age (Years)
Neonate 4 94 1.0 1.0
Infant 16 199 1.89 (0.61–5.81) 1.29 (0.39–4.23)
Toddler 6 120 1.17 (0.32–4.28) 0.39 (0.09–1.74)
Pre-school age 1 68 0.36 (0.04–3.16) 0.18 (0.02–1.87)
School age 11 70 3.69 (1.13–12.08) ** 1.94 (0.53–7.12)
Adolescent 8 37 5.08 (1.44–17.90) ** 2.69 (0.67–10.74)
Use of CNS medicines
No 24 155 1.0 1.0
Yes 22 433 2.56 (1.40–4.70) ** 2.09 (1.01–4.32) **
Use of endocrine medicines
No 35 537 1.0 1.0
Yes 11 51 3.31 (1.58–6.91) ** 3.38 (1.40–8.15) **
Use of other medicines
No 42 572 1.0 1.0
Yes 4 16 3.40 (1.09–10.64) ** 1.79 (0.37–8.65)
Use of anti-histamine and anti-allergic
No 40 584 1.0 1.0
Yes 6 4 21.90 (5.94–80.80)* 32.51 (5.99–176.45)*
Presence of infectious disease
No 5 185 1.0 1.0
Yes 41 403 3.76 (1.46–9.68) ** 3.43 (1.19–9.91) **
* p < 0.001, **p < 0.05
a15 patient admissions were not taking any medications. N = 619, ‘Yes’ = 46; ‘No’ = 573
bThe odds ratio was adjusted for number of medications, length of hospital stay, age (years), use of CNS medicines, use of endocrine medicines, use of other
medicines, use of antihistamine and anti-allergic and presence of infectious disease
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anti-allergic medications give a clue for further evaluation
of ADEs.
We found that ADEs increased with the length of hos-
pital stay akin to a finding by Holdsworth et al. [41]. Santos
et al. [13] have also reported that children with longer
length of stay, greater number of medications had
higher ADR incidence. In one study among adults
[42], the authors identified that exposure to psychoactive
and CV drugs were independent correlates of preventable
ADEs. This was similar to our findings which showed
CNS and endocrine medicines and presence of infectious
disease as strong predictors of ADE.
This study has limitations, however. It is a single center
study and therefore might not be generalized to other
hospitals in Ethiopia. The incidence of ADEs might
have been underestimated as some ADES may not
have been recorded in the charts and may thus have not
been detected. Any event that has occurred in patients
with less than 24 h of hospital stay was not included but it
was unlikely that we missed those events as such events
required prolonged stay.
Conclusion
The incidence of ADE was high among children hospital-
ized to JUSH and ADEs were more likely to occur among
children with longer length of hospital stay, presence of
infectious disease, use of CNS, endocrine and anti-
histamine medications. Anti-infectives were the most
commonly implicated drugs for development of ADEs.
Only one third of ADEs were found to be preventable.
Though most of the ADEs were evaluated to cause tempor-
ary harm, clinically significant number of children suffered
from permanent harm. This calls for a strategy to prevent
the occurrence and consequences of ADEs in the pediatric
ward of JUSH including education of nurses/physicians.
Additional file
Additional file 1: Trigger tools or clues for a focused chart review.
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